Afinitor (Everolimus)

everolimus 5 mg tablet, 30 · ORAL · PBS code 11257L

STREAMLINED

What it costs

AU$796.7 PBS-determined price per 30 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2018-03-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV clear cell variant renal cell carcinoma (RCC)

Continuing treatment beyond 3 months

Patient must have received an initial authority prescription for this drug for this condition; AND

Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST); AND

The treatment must be the sole PBS-subsidised therapy for this condition.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.